

## Comparative Analysis of Intimal Hyperplasia After Sirolimus-Eluting Stent and Thin-Strut Bare-Metal Stent Implantation in Small Coronary Arteries

Fernando Stuchi Devito, Amanda G. M. R. Sousa, Fausto Feres, Alexandre Antonio Cunha Abizaid, Rodolfo Staico, Luis Alberto Piva Mattos, Luis Fernando Leite Tanajura, Andréa C. L. S. Abizaid, Áurea Jacob Chaves, J. Eduardo M. R. Sousa  
*Instituto Dante Pazzanese de Cardiologia - São Paulo, SP*

### OBJECTIVE

This study aimed at evaluating reduction in intimal hyperplasia volume following angioplasty using sirolimus-eluting stents (Cypher™) compared with thin-strut bare-metal stents (Pixel™) in patients with small vessels.

### METHODS

Eighty patients with coronary artery disease were prospectively included in two consecutive series, the first using sirolimus-eluting stents (50) and the second using bare-metal stents (30).

### RESULTS

The use of sirolimus-eluting stents reduced: in-stent net volume obstruction [5.0% (SE = 0.77) x 39.0% (SE = 4.72),  $p < 0.001$ ], in-stent late loss [0.25 mm (SE = 0.03) x 1.11 mm (SE = 0.13),  $p < 0.001$ ], in-segment late loss [0.30 mm (SE = 0.04) x 0.83 mm (SE = 0.11),  $p < 0.001$ ], in-stent restenosis (0% x 33.3%,  $p < 0.001$ ) and in-segment restenosis (4% x 36.7%,  $p < 0.001$ ). The event-free survival rate was 96% in the sirolimus-eluting stent group versus 86.7% in the bare-metal stent group (BMS) ( $p = 0.190$ ).

### CONCLUSION

Sirolimus-eluting stents are superior to thin-strut bare-metal stents in reducing intimal hyperplasia (less in-stent obstruction and less late lumen loss) in patients with small vessels. The use of these stents significantly reduced angiographic restenosis at eight months.

### KEY WORDS

Stent, restenosis, small vessels.

Treatment of patients with coronary artery disease (CAD) in small vessels currently accounts for up to 40% of all percutaneous revascularizations<sup>1,2</sup>. Restenosis may be as high as 50% after bare-metal stenting in small vessels, depending on lesion length and on the presence of diabetes mellitus<sup>3-9</sup>. Intimal hyperplasia is the primary mechanism of in-stent restenosis, and therapies focused on inhibiting neointimal growth should reduce restenosis<sup>10,11</sup>.

In the FIM and RAVEL trials, the use of sirolimus-eluting stents in patients with vessels larger than 3.0 mm, compared with bare-metal stents, resulted in marked reduction in intimal hyperplasia<sup>12,14</sup>. In the SIRIUS trial, angiographic restenosis was reduced from 36.3% after bare-metal stenting to 8.9% after sirolimus-eluting stenting ( $p < 0.001$ ). However, in a subanalysis of this same trial, restenosis after sirolimus-eluting stenting in vessels with mean reference diameter of 2.29 mm was higher (18.4%) when compared to large vessels (1.9%), calling into question the role of these endoprostheses in patients with small-vessel disease<sup>15</sup>.

At the same time, stents have been structurally modified to become thinner, and thin-strut stents were assessed in the ISAR-STEREO-2 trial, the results of which were decreased intimal hyperplasia<sup>16,17,18</sup>. One study by Garcia et al evaluating these stents in patients with small vessels reported 19.3% of restenosis and only 4.1% of target-vessel revascularization. Since then, these thin-strut stents have been considered the best option among uncoated stents for the treatment of small vessels<sup>19,20</sup>.

In this study, we compared intimal hyperplasia in small vessels (reference diameter  $< 2.75$  mm) following either sirolimus-eluting or bare-metal stent implantation based on intimal hyperplasia volume measured by intravascular ultrasound.

## METHODS

From December 2002 to December 2003, patients with established diagnosis of coronary artery disease and candidates for elective percutaneous coronary intervention (PCI) were prospectively included in this study according to the following criteria: age equal to or older than 18 years; diagnosis of stable angina defined by the Canadian Society Classification (CSC I, II, III or IV), silent ischemia, unstable angina (Braunwald classification IB, IC, IIB, IIC), or myocardial infarction  $>$  seven days; reference vessel diameter between 2.20 mm and 2.75 mm (quantitative coronary angiography); *de novo* native coronary artery lesion with target-lesion stenosis between 50% and 99% and  $\leq 30$  mm in length. Exclusion criteria were: presence of cardiogenic shock; serum creatinine  $> 2.0$  mg/dL; peripheral vascular disease; known hypersensitivity or contraindication to heparin, acetylsalicylic acid (ASA), ticlopidine or clopidogrel; end-stage diseases associated with limited life expectancy (less than a year); left

ventricular ejection fraction  $\leq 30\%$ ; excessive target-vessel tortuosity, making intracoronary ultrasound difficult to perform; target-lesion  $\geq 50\%$  in unprotected left main coronary artery; ostial lesions; target-lesions located at a bifurcation involving side branches  $\geq 2.0$  mm in diameter, and the presence of thrombus at the target site. The study protocol was approved by the Institutional Research Ethics Committee of the Hospital.

Patients were nonrandomly assigned to the trial and divided into two sequential treatment groups, the first using the Cypher™ stent (coated with sirolimus) and the other using the Multilink Rx Pixel™ stent (uncoated). According to the standard technique, aspirin 200 mg/day was administered at least 24 hours prior to intervention and a thienopyridine (ticlopidine or clopidogrel), during two months. Ticlopidine dosage was 250 mg twice daily (started at least 48 hours prior to intervention). Clopidogrel was given in a loading dose of 300 mg followed by and 75 mg daily (at least 24 hours prior to intervention). Unfractionated heparin was administered by intravenous bolus of 100 IU/kg. The use of both glycoprotein IIb/IIIa inhibitor and predilation was left to the operators' discretion. Predilation balloons should be undersized at least 0.5 mm to the reference vessel diameter, in addition to being shorter than the chosen stent. Postdilation balloons (pressure  $> 12$  atm) also should be shorter than the implanted stent. When multiple stents were required, they had to overlap by 3 or 4 mm to prevent gaps between the endoprostheses. At the end of the procedure, all patients underwent ultrasound evaluation. Outpatient visits following discharge were made one, three, six, and eight months after PCI, when other coronary angiography and ultrasound examinations were scheduled.

As for the endovascular prostheses used, the Cypher™ stent (with sirolimus) manufactured by Cordis, Johnson & Johnson, is made of 316L stainless steel coated with a 50/50 combination of two non-erodible polymers, polyethylene-co-vinyl acetate (PEVA) and poly n-butyl methacrylate (PBMA), mixed with sirolimus. A topcoat of PBMA polymer is applied to the stent surface. All stents contain 148  $\mu\text{g}$  of sirolimus per  $\text{cm}^2$  of metal surface area and, in this formulation, the drug is released gradually over a prolonged period (95% is released up to 28 days after implantation). The Multilink Rx Pixel™, manufactured by Guidant™, is a stainless-steel, uncoated, balloon-expandable stent especially designed for small vessels. This thin-strut stent (0.05 mm) is composed of only five rings, allowing complete circumferential coverage with less metal.

Off-line quantitative angiographic analysis was performed using the CMS™ device (Medis, Netherlands) at end-diastolic frames. The frame displaying the most severe lesion, before and after stent implantation, would be chosen for analysis. Minimal lumen diameter (MLD) and late lumen loss (LLL) were measured at the in-stent

and in-lesion segments (in-stent plus the 5 mm proximal and distal to the endoprosthesis) at the following time points: preintervention, postintervention, and at follow-up coronary angiography.

Ultrasound assessment was performed using the Clear View™ (CVIS, Boston Scientific Corporation) and a 40-MHz catheter. Using an automated pullback system of the ultrasound catheter at 0.5 mm/s, image acquisition was continuous, starting at least 10 mm distal to the target lesion and advancing up to the aorto-ostial junction. The acquired images were analyzed by the echoPlaque™ 2 software (Indec Systems Inc. U.S.). Angiographic and ultrasound images were analyzed at the core lab of the Department of Invasive Cardiology of Institute Dante Pazzanese of Cardiology. Using Simpson's formula, stent, lumen and intimal hyperplasia volumes were calculated<sup>12</sup>. As this study involved stents of different lengths, these volumes were calculated in absolute numbers (mm<sup>3</sup> per patient) and correlated to the mean area for each variable (mm<sup>2</sup>). In-stent volume obstruction was calculated as the ratio between intimal hyperplasia volume and stent volume x 100. Incomplete stent apposition was evaluated and defined by the separation of one or more stent strut from the vessel wall with evidence of blood flow between the stent and the vessel wall (seen as blood speckles on the ultrasound image). When more than one incomplete stent apposition was detected, the circumferential angle of malapposition was reported. The degree of malapposition was also described and calculated by the sum of distances between the areas with malapposition<sup>14</sup>.

In-stent and in-segment restenosis were defined by the classic binary criterion (stenosis > 50% at follow-up angiography). Success was defined by postprocedural residual stenosis lower than 10%, in the absence of major complications (death, infarction, and emergency surgery).

The primary endpoint was to evaluate, at the term of eight months, the in-stent volume obstruction occupied by intimal hyperplasia. Secondary endpoints included: In-stent and in-segment MLD and late loss, binary restenosis, and incidence of major adverse cardiac events (death, infarction, and target-lesion revascularization).

Calculation of sample size was based on the assumption of 40% an in-stent volume obstruction for bare-metal stents and of only 10% for sirolimus-eluting stents (SD = 30), that is, a relative reduction of 75%<sup>21,22</sup>. With a two-tailed hypothesis test, alpha level of 0.05 and statistical power of 90%, 21 patients would be necessary in each group for the primary endpoint to be demonstrated. Considering possible losses and attempting to include the higher number of patients necessary to achieve better distribution of clinical, angiographic, and IVUS variables, we planned to enroll 30 patients in each group. Owing to the availability of fifty patients who were being treated with sirolimus-eluting stents at that time in the institution,

the first fifty patients were sequentially treated with these endoprostheses (sirolimus-eluting stents), and the other patients were treated with bare-metal stents.

Categorical variables were expressed as absolute and relative frequencies (percentages), and quantitative variables, as means and standard errors. Pearson's chi-square test or Fisher's exact test was used to compare both groups' categorical variables, when necessary. Student's t test for independent samples was used to evaluate quantitative variables in a single time point. Quantitative variables measured at three time points (before, immediately after the procedure and at eight months) were determined by Generalized Linear Models with repeat measurements. Two aspects were considered in these models: group (sirolimus-eluting stents and bare-metal stents) and time point (pre-, post-, and late), and comparisons were made between groups (sirolimus-eluting stents vs. bare-metal stents at each time point) and in each group (pre- x post- x late for each group). Statistical analyses were performed using SPSS version 11.0 and SAS version 8.01. Significance level was set at 0.05.

## RESULTS

Eighty patients were included in this study: the first fifty were sequentially treated with sirolimus-eluting stent (Cypher™) and the last thirty, with Multilink Rx Pixel™ (uncoated). Clinical characteristics of patients in both treatment groups are shown in Table 1, angiographic characteristics in Table 2, as well as the technical variables of procedure in Table 3. During follow-up, 94% of the patients underwent angiographic evaluation. Results of in-stent quantitative coronary angiography (QCA) are shown in Table 4. Mean reference vessel diameter [2.44 mm (SE = 0.02) x 2.37 mm (SE = 0.03), p = 0.075] and mean length of treated lesions [13.75 mm (SE = 0.92) x 12.87 mm (SE = 0.53), p = 0.498] were similar in both groups. Mean minimal lumen diameter did not differ between groups, either in the preprocedural (p = 0.926) or in the postprocedural findings (p = 0.952), but at eight months the vessels treated with sirolimus-eluting stents had increased MLD [2.14 mm (SE = 0.03) x 1.28 mm (SE = 0.13), p < 0.001]. This was due to the late lumen loss, which was significantly lower in the sirolimus group [0.25 mm (SE = 0.03) x 1.11 mm (SE = 0.13), p < 0.001].

No in-stent restenosis was found following sirolimus-eluting stenting, contrary to 33.3% of restenosis following bare-metal stenting (p < 0.001). Individual MLD variations, as well as in the stenosis rate over time, in both treatment arms are shown in Figure 1. These angiographic measurements obtained before and after the procedure are quite consistent in both treatment groups, but in late evolution, higher variability is observed with bare-metal stents. In-segment analysis showed less late

**Table 1 – Key clinical characteristics of the eighty patients with small vessels treated with either sirolimus-eluting stents or bare-metal stents**

Variables	Sirolimus-eluting Stents (n = 50)	Bare-metal Stents (n = 30)	p
Males	31 (62.0%)	17 (56.7%)	0.64
Mean age in years (SE)	59 (1.6)	56 (1.7)	0.338
<b>CAD Risk factors</b>			
Arterial hypertension	39 (78.0%)	24 (80.0%)	0.832
Diabetes mellitus	20 (40.0%)	9 (30.0%)	0.368
Smoking			
Current	12 (24.0%)	9 (30.0%)	0.588
Past	17 (34.0%)	7 (23.3%)	
Hypercholesterolemia	32 (64.0%)	19 (63.3%)	0.952
<b>Coronary history</b>			
CABG	3 (6.3%)	1 (3.3%)	0.500
PCI	11 (22.4%)	11 (36.7%)	0.171
Previous myocardial infarction	21 (43.8%)	11 (36.7%)	0.536
<b>Clinical presentation</b>			
Asymptomatic with positive tests	12 (24.0%)	5 (16.7%)	0.407
Stable angina	22 (44.0%)	18 (60.0%)	
Unstable angina	16 (32.0%)	7 (23.3%)	

SE = standard error; CABG = coronary artery bypass grafting; PCI = percutaneous coronary intervention; n = number of patients; CAD - coronary artery disease

**Table 2 – Qualitative angiographic characteristics of the eighty patients with small vessels treated with either sirolimus-eluting stents or bare-metal stents**

Variables	Sirolimus-eluting stents (n = 50)	Bare-metal stents (n = 30)	p
<b>Vessel treated</b>			
AD	20 (40.0%)	9 (31.0%)	0.740
Cx	9 (18.0%)	6 (20.6%)	
RC	10 (20.0%)	4 (13.7%)	
Dg	6 (12.0%)	5 (17.2%)	
Mg	5 (10.0%)	5 (17.2%)	
<b>Type of lesion</b>			
A	2 (4.0%)	-	0.001
B1	32 (64.0%)	10 (33.3%)	
B2	12 (24.0%)	19 (63.3%)	
C	4 (8.0%)	-	
<b>Number of affected vessels</b>			
One	38 (76.0%)	15 (51.7%)	0.047
Two	11 (22.0%)	11 (37.9%)	
Three	1 (2.0%)	3 (0.3%)	

\*According to the American Heart Association/American College of Cardiology classification. AD = anterior descending; Cx = circumflex; RC = right coronary; Dg = diagonal; Mg = marginal

lumen loss with sirolimus-eluting stents than with bare-metal stents [0.30 mm (SE = 0.04) x 0.83 mm (SE = 0.11),  $p < 0.001$ , respectively], in-segment restenosis being significantly lower in the sirolimus arm [4% x 36.7%, ( $p < 0.001$ )].

Eighty per cent of the patients underwent intravascular ultrasound examination. Intravascular ultrasound analysis showed that mean intimal hyperplasia volume was 5.0 mm<sup>3</sup> (SE = 0.77) in the sirolimus-stent group versus 27.5 mm<sup>3</sup> (SE = 3.60) in the BMS-group ( $p < 0.001$ ). Mean intimal hyperplasia cross-sectional area was smaller in the sirolimus-stent group compared with the BMS-group [0.24 mm<sup>2</sup> (SE = 0.03) x 1.62 mm<sup>2</sup> (SE = 0.19),  $p <$

0.001], as was mean in-stent volume obstruction [5% (SE = 0.77) x 39% (SE = 4.72),  $p < 0.001$ ]. No stent malapposition was found in either group.

Stent implantation was successful in all the patients, without major in-hospital complications (death, myocardial infarction, or emergency revascularization surgery). No patient in this study was given glycoprotein IIb/IIIa inhibitor. Moreover, there were no in-stent thromboses, nonfatal myocardial infarctions nor deaths, either at 30 days or at eight months. All patients were clinically evaluated during this period, and two patients (4%) treated with sirolimus-eluting stents required repeat target-lesion revascularization. In these cases, additional

**Table 3 – Clinical characteristics of procedures performed in the eighty patients with small vessels treated with either sirolimus-eluting stents or bare-metal stents**

Variable	Sirolimus-eluting stents	Bare-metal stents	p
<b>Stent diameter (mm)</b>			0.029
2.25	4 (8.0%)	1 (3.3%)	
2.50	38 (76.0%)	29 (96.7%)	
2.75	8 (16.0%)	-	
Mean stent diameter (mm) (SE)	2.52 (0.02)	2.49 (0.01)	0.144
<b>Stent length (mm)</b>			<0.001
8	-	1 (3.3%)	
13	-	10 (33.3%)	
18	42 (84.0%)	11 (36.7%)	
23	6 (12.0%)	8 (26.7%)	
33	2 (4.0%)	-	
Mean stent length (mm) (SE)	19.20 (0.46)	17.33 (0.79)	0.046
SL/LL (SE)	1.4 (0.08)	1.5 (0.05)	0.207
Mean MIP (atm) (SE)	14.9 (0.36)	14.4 (0.35)	0.332
<b>Number of stents used</b>			0.384
One	46 (92.0%)	30 (100.0%)	
Two	3 (6.0%)	-	
Three	1 (2.0%)	-	
Balloon predilation (n) (%)	39 (78.0%)	17 (58.6%)	0.068
Balloon postdilation (n) (%)	13 (26.5%)	4 (14.3%)	0.213

*SE = standard error; SL/LL = stent length-to-lesion length ratio; MIP = maximal stent implantation pressure; n = number*

**Table 4 – Variables of in-stent and in-segment quantitative coronary angiography before, immediately after the procedure, and at eight months**


	Sirolimus-eluting stents	Bare-metal stents	p
RD (mm) (SE)	2.44 (0.02)	2.37 (0.03)	0.075
Lesion length (mm) (SE)	13.75 (0.92)	12.87 (0.52)	0.498
<b>MLD (mm) (SE)</b>			
Preprocedural*	0.71 (0.03)	0.72 (0.04)	0.926
Postprocedural*	2.38 (0.02)	2.39 (0.02)	0.952
At eight months	2.14 (0.03)	1.28 (0.13)	<0.001
<b>Stenosis rate (%) (SE)</b>			
Preprocedural*	70.64(1.09)	70.57(1.74)	0.980
Postprocedural*	6.78 (0.30)	5.86 (0.30)	0.747
At eight months	13.51(1.15)	46.82 (5.50)	<0.001
Acute gain (mm) (SE)	1.67(0.03)	1.69(0.03)	0.661
In-stent late loss (mm) (SE)	0.25 (0.03)	1.11 (0.13)	<0.001
In-segment late loss (mm) (SE)	0.30 (0.04)	0.83 (0.11)	<0.001
In-stent restenosis (n) (%)	0	10 (33.3)	<0.001
In-segment restenosis (n) (%)	2 (4)	11 (36.7)	<0.001

*RD = reference diameter; MLD = minimal lumen diameter; SE = standard error; \* all comparisons of MLD and restenosis rate, preprocedural, postprocedural and at eight months, were significant, with p < 0.001*

angioplasty was performed with the implantation of another sirolimus-eluting stent. Six patients in the BMS-group experienced myocardial ischemia symptoms (20.0%), and four (13.3%) required repeat target-lesion revascularization (TLR): two balloon angioplasty and two coronary artery bypass surgery (CABG). Thus, although event-free survival and TLR-free survival were lower in the sirolimus-stent group when compared with the BMS-group, no statistically significant difference was found regarding these clinical outcomes in either group (96% x 86.7%; p = 0.190).

## DISCUSSION

This study showed that sirolimus-eluting stenting in patients with small vessels is associated with a lesser degree of intimal hyperplasia compared with the reparative response following bare-metal stenting, and thus results in a lower rate of in-stent and in-segment restenosis. Clinical variables in this study characterized groups of patients with at least moderate complexity for percutaneous coronary intervention. Among all characteristics, it is worth noting the high prevalence



of diabetes mellitus: 40% in the sirolimus-eluting stent group and 30% in the BMS-group ( $p = 0.368$ ). In most randomized trials comparing ballooning versus stenting in patients with small vessels, with the exception of the CHIVAS<sup>23</sup> and RAP<sup>24</sup> trials, the prevalence of diabetes was lower than 30%, ranging from 12% and 20%. Even in the era of sirolimus-eluting stents, the SVELT<sup>25</sup> was the trial that included the highest number of diabetics (26.7%). In the RAVEL<sup>14</sup>, SIRIUS, C-SIRIUS<sup>26</sup>, E-SIRIUS<sup>27</sup> and SES-SMART<sup>28</sup> trials, this subgroup accounted for 16%, 25%, 24%, 23%, and 19.4%, respectively.

The most relevant IVUS finding was the beneficial mechanism involved with sirolimus-eluting stent compared with bare-metal stent, that is, inhibition (in 87%) of excessive intimal hyperplasia evaluated by in-stent volume obstruction. This finding of marked decrease in in-stent intimal hyperplasia has been consistent in all sirolimus-eluting stent trials that used IVUS as the evaluation tool. Mean intimal hyperplasia cross-sectional area obtained in this investigation ( $0.24 \text{ mm}^2$ ) was similar to that observed in the SVELT<sup>25</sup> trial ( $0.08 \text{ mm}^2$ ), as well as in trials of sirolimus-eluting stents in larger vessels, such as the RAVEL<sup>14</sup> and the SIRIUS<sup>15</sup> ( $0.11 \text{ mm}^2$  and  $0.50 \text{ mm}^2$ , respectively), meaning that

intimal hyperplasia inhibition with these stents does not depend on vessel diameter. However, mean intimal hyperplasia associated with the thin-strut, bare-metal stents used in this study (Pixel™) was  $1.62 \text{ mm}^2$ , lower than that found in the DANTE<sup>29</sup> trial ( $3.05 \text{ mm}^2$ ) and in the respective arms of the RAVEL<sup>14</sup> and SIRIUS<sup>15</sup> trials ( $2.05 \text{ mm}^2$  and  $2.70 \text{ mm}^2$ , respectively), which used a thicker strut model.

Moreover, no incomplete apposition of stent struts was found in either group. Unlike in large vessels, stent placement in small vessels is performed with a higher stent-to-vessel diameter ratio, favoring stent strut impaction in the atheromatous plaque. Therefore, incomplete stent apposition is usually less frequent in small vessels. In the RAVEL<sup>14</sup> trial, for example, mean vessel diameter in ten patients with incomplete stent apposition was  $3.16 \text{ mm}$  ( $\text{SD} = 0.57$ ), whereas that of 38 patients with well-apposed stents was  $2.79 \text{ mm}$  ( $\text{SD} = 0.43$ ), ( $p < 0.05$ ).

In the last decade, recommendations for bare-metal stenting emphasized the need to obtain as much lumen as possible to accommodate hyperplasia and, thus, reduce restenosis. However, in the investigation of drug-eluting stents showing significant decrease in-stent

intimal hyperplasia, as in the SIRIUS<sup>15</sup> trial, the finding of border effects attracted special attention, because they accounted for the recurrences in this study. Based on this new perspective, additional technical observations were implemented to guide stent implantation.

One of these aspects is lesion coverage, because an incomplete metallic coverage in sirolimus-eluting stent implantation may affect late results. In this study, stent length-to-lesion length ratio was 1.4, and in the C-SIRIUS<sup>26</sup> and E-SIRIUS<sup>27</sup> trials was even higher (1.7 and 1.8, respectively), as well as in the RAVEL<sup>14</sup> trial, in which no follow-up restenosis was found during the first year. Although lesions were more complex in the C-SIRIUS<sup>26</sup> trial than those randomized in the RAVEL<sup>14</sup> trial, requiring more than one stent per lesion in 48% of the cases (67% of which with overlapping stents), restenosis rate was very low (0% in-stent and 2.3% in-segment), demonstrating that longer stents are better, even when more than one stent is required. In this case, this should be done with a 2- or 3 mm overlap, to prevent target lesion ends from being exposed to balloon trauma and, thus, to intimal proliferation.

Among the limitations of this study, the lack of randomization should be noted. Logistics regarding limited availability of sirolimus-eluting stents prevented inclusion for a one-year period anticipated by the study design. Nevertheless, it must be emphasized that both treatment groups were quite homogeneous with respect to all variables related to lesion recurrence and thus minimized this aspect. In addition, the way patients were sequentially

included and also the stents' structural differences prevented a blind analysis of results. However, result analysis by quantitative angiography and intravascular ultrasound, with accurate and objective measurements, performed at a laboratory with large experience in this field, minimizes this aspect.

In view of these findings, we believe that treatment of vessels with reference diameter lower than 2.75 mm changed dramatically with the advent of sirolimus-eluting stents. Moreover, in the near future, as the costs of endoprostheses decrease, the use of sirolimus-eluting stents in patients with small vessels may be even more cost-effective compared with bare-metal stents, owing to a reduction in target-lesion revascularization, hospital admissions, and drug prescriptions.

Therefore, we can conclude that sirolimus-eluting stenting in patients with small vessels leads to reduced intimal hyperplasia, as evaluated by intravascular ultrasound, compared with thin-strut, bare-metal stenting. Angiographic measurements related to late results (degree of stenosis, late lumen loss, and restenosis) are significantly lower after sirolimus-eluting stent implantation. Late minimal lumen diameter is greater following sirolimus-eluting stenting compared with bare-metal stenting. Target-lesion revascularization is about 10% lower in patients treated with sirolimus-eluting stents, even though this difference was not statistically significant in the present study.

No potential conflict of interest relevant to this article was reported.

## REFERENCES

1. Sociedade Latino-americana de Cardiologia Intervencionista [homepage]. Informe 1988-2002 sobre produtividade em Cardiologia na América Latina. [citado em 8 de fevereiro de 2005]. Disponível em: <http://www.solaci.org>.
2. Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista [homepage]. Central Nacional de Intervenções Cardiovasculares (CENIC): Estatística - Balão vs. stent. [citado em 16 de mar 2004]. Disponível em: <http://www.sbhci.org.br>.
3. Akiyama T, Moussa I, Reimers B et al. Angiographic and clinical outcome following coronary stenting of small vessels: a comparison with coronary stenting of large vessels. *J Am Coll Cardiol* 1998; 32: 1610-8.
4. Elezi S, Kastrati A, Neumann FJ et al. Vessel size and long-term outcome after coronary stent placement. *Circulation* 1998; 98: 1875-80.
5. Al Suwaidi J, Yeh W, Williams DO et al. Comparison of immediate and one-year outcome after coronary angioplasty of narrowing <3 mm with those > or =3 mm (the National Heart, Lung, and Blood Institute Dynamic Registry). *Am J Cardiol* 2001; 87: 680-6.
6. Briguori C, Nishida T, Adamian M et al. Coronary stenting versus balloon angioplasty in small coronary artery with complex lesions. *Catheter Cardiovasc Interv* 2000; 50: 390-7.
7. Suselbeck T, Latsch A, Siri H et al. Role of vessel size as a predictor for the occurrence of in-stent restenosis in patients with diabetes mellitus. *Am J Cardiol* 2001; 88: 243-7.
8. Moreno R, Fernandez C, Alfonso F et al. Coronary stenting versus balloon angioplasty in small vessels. *J Am Coll Cardiol* 2004; 43: 1964-72.
9. Ho KKL, Sernechia C, Rodriguez O et al. Predictors of angiographic restenosis after stenting: pooled analysis of 1197 patient with protocol-mandated angiographic follow-up from 5 randomized trials. *Circulation* 1998; 98 (Suppl I): I-362.
10. Mintz GS, Kent KM, Pichard AD et al. Intravascular ultrasound insights into mechanisms of stenosis formation and restenosis. *Cardiol Clin* 1997; 15: 17-29.
11. Nikol S, Huehns TY, Hofling B. Molecular biology and post-angioplasty restenosis. *Atherosclerosis* 1996; 123: 17-31.
12. Sousa JE, Costa MA, Abizaid AC et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. *Circulation* 2001; 104: 2007-11.
13. Sousa E. FIM 4 years. Presented to TCT 2004. [cited feb 5 2005]. Available from: <http://www.tctmd.com/expert-presentations/slides.html>.
14. Morice MC, Serruys PW, Sousa JE et al. RAVEL Study Group. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. *N Engl J Med* 2002; 346: 1773-80.
15. Moses JW, Leon MB, Popma JJ et al, SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. *N Engl J Med* 2003; 349: 1315-23.
16. Hoffmann R, Mintz GS, Haager PK et al. Relation of stent design and stent surface material to subsequent in-stent intimal hyperplasia in coronary arteries determined by intravascular ultrasound. *Am J Cardiol* 2002; 89: 1360-4.

17. Kastrati A, Mehilli J, Dirschinger J et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. *Circulation* 2001; 103: 2816-21.
18. Pache J, Kastrati A, Mehilli J et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. *J Am Coll Cardiol* 2003; 41: 1283-8.
19. Multi-Link Pixel TM Registry – Six Months Results. 2005 [cited feb 8 2005]. Available from: [http://www.tctmd.com/images/Pixel\\_WP](http://www.tctmd.com/images/Pixel_WP)
20. Garcia E. Randomized Trial of Direct Stenting With the Pixel Stent in Small Vessels. *Transcatheter Cardiovascular Therapeutics (TCT)* 2003. [cited feb 5, 2005]. Available from: <http://www.tctmd.com/expert-presentations/slides.html>.
21. Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). The ERASER Investigators. *Circulation* 1999; 100: 799-806.
22. Dussaillant GR, Mintz GS, Pichard AD et al. Small stent size and intimal hiperplasia contribute to restenosis: a volumetric intravascular ultrasound analysis. *J Am Coll Cardiol* 1995; 26: 720-4.
23. Muramatsu T, Iwasaki K, Inoue NI. Coronary heart disease stenting in small vessels versus balloon angioplasty study (CHIVAS): a randomized prospective multicenter trial (abstr). *J Am Coll Cardiol* 2002; 39 (Suppl A): 50A.
24. Garcia E, Gomez-Recio M, Moreno R. Stent reduces restenosis in small vessels: results of the RAP study (abstr). *J Am Coll Cardiol* 2001; 37 (Suppl. A): 17A.
25. Souza E, for the SVELT investigators. *Transcatheter Cardiovascular Therapeutics (TCT)* 2004. [cited feb 5, 2005]. Available from: <http://www.tctmd.com/expert-presentations/slides.html>.
26. Schampaert E, Cohen EA, Schluter M et al. C-SIRIUS Investigators. The canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). *J Am Coll Cardiol* 2004; 43: 1110 -5.
27. Schofer J, Schluter M, Gershlick AH et al. E-SIRIUS Investigators. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). *Lancet* 2003; 362: 1093-99.
28. Ardissino D, Cavallini C, Bramucci E et al. SES-SMART Investigators. Sirolimus-Eluting vs uncoated Stents for Prevention of Restenosis in Small Coronary Arteries. *JAMA* 2004; 292: 2727-34.
29. Chaves AJ. Análise volumétrica da hiperplasia intimal intra-stent em pacientes diabéticos tratados com e sem abciximab. São Paulo, 2004. 107p. Tese (Doutorado) – Faculdade de Medicina, Universidade de São Paulo.